tbuckley/cabot-search huggingface dataset:
Medicolegal Cases: Abstracts of Court Decisions of Medicolegal Interest, 1926-1930.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Laughter
Authors: Donald W. Black
Journal: JAMA (1984)

Knowledge of laughter, other than of its clinical manifestations, is tenuous. A unique, ubiquitous human phenomenon, laughter has largely been neglected by medical investigators and relegated to philosophers and naturalists, particularly Darwin. Clinical manifestations are well described, but the many physiological changes accompanying laughter are not. Neurological pathways remain speculative, and those described are based on pathological evidence. Laughter, as a behavior, has many causes, including humor, incongruity, relief, and a sense of well-being. Laughter may have developed for its cathartic effects and adaptive value. As an evolutionary device, laughter may have served to thwart aggression, spread information, and preserve social unity. Laughter's potential for a variety of clinical uses awaits future investigation. (<i>JAMA</i>1984;252:2995-2998)
The Croonian Lectures on Some Points in the Pathology and Treatment of Typhoid Fever
Authors: W. Cayley
Journal: BMJ (1880)

AN'OTHER abdominal symptom remains to be consideredl in relation to the bathing, viz., tympanites.When great, not only is it in itself a cause of much distress and even danger, but it indicates either very severe iiervous depression or serious local lesions.The actual cause of the condition is, no doubt, paralysis or loss of tone of the muscular coat of the intestine.Sometimes it comes on early, before the middle of the second week, and is then a most ominous symptom, and is an indlication of a profound shock to the nervous system.This early tym- panites is, I believe, most bencficially influenced by reducing the tem- perature by bathing and cold compresses, together with free stimula- tion.The tympanites of the later stages of the fever is often due, in addition to the local lesions, either to actual peritonitis, or, at any rate, extensive and deep intestinal ulceration, and demands, besides the local application of cold to the surface of the belly, the free use of opium.I cannot say I have ever seen much advantagcresult from the
From the Centers for Disease Control and Prevention. Occupational silicosis--Ohio, 1989-1994
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ovarian Cancer
Authors: MARTIN E. KATZ
Journal: Annals of Internal Medicine (1982)

Letters and Corrections1 April 1982Ovarian CancerMARTIN E. KATZ, M.D., PETER E. SCHWARTZ, M.D., DANIEL S. KAPP, M.D., SHARON LUIKART, M.D.MARTIN E. KATZ, M.D.Search for more papers by this author, PETER E. SCHWARTZ, M.D.Search for more papers by this author, DANIEL S. KAPP, M.D.Search for more papers by this author, SHARON LUIKART, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-4-532 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Dr. Bruckner's letter in the November 1981 issue written in response to our recent review of epithelial carcinoma of the ovary raises several important questions about the results of therapy in women with ovarian cancer. It is clear that all clinical studies reported need to be analyzed for important variables that may modify response rates, disease-free survival, and overall survival. These important variables include stage of disease, degree of tumor differentiation, previous exposure to radiation therapy and chemotherapy, performance status, and completeness of restaging. It is also important that clinical trials be done in a prospective, randomized...References1. BRUCKNERCOHENGOLDBERG HCJ. Differentiation of ovarian cancer as a survival determinant for adriamycin and cisplantin ± cyclophosphamide and hexamethylmelamine [Abstract]. Proc Am Soc Clin Oncol. 1980;21:428. Google Scholar2. EHRLICHEINHORNSTEHMANROTH CLFL. Response, second look status and survival in stage III-IV epithelial ovarian cancer treated with cis-dichloro-diammineplatinum, Adriamycin and cyclophosphamide [Abstract]. Proc Am Soc Clin Oncol. 1980;21:423. Google Scholar3. HALLDIASIOGOPLERUD DRD. Cisplatinum in gynecologic cancer. I. Epithelial ovarian cancer. Am J Obstet Gynecol. 1981;141: 299-304. CrossrefMedlineGoogle Scholar4. COHENDEPPEGUSBERG CGS. The results of therapeutic end staging laparotomy (second look surgery) in patients with epithelial cancer of the ovary, stages III and IV, treated by surgery and multidrug chemotherapy containing cisplatin [Abstract]. Proc Am Soc Clin Oncol. 1981;22:392. Google Scholar5. GRECOOLDHAMRICHARDSONHANDEBURNETTJULIAN FRRKLC. Limited stage III ovarian cancer—a potentially curable neoplasm [Abstract]. Proc Am Soc Clin Oncol. 1980;21:422. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Yale University New Haven, CT 06510 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1982Volume 96, Issue 4Page: 532-533KeywordsChemotherapyClinical trialsDisease free survivalOvarian cancerOvariesRadiation therapy Issue Published: 1 April 1982 PDF DownloadLoading ...
RENAL BLOOD PRESSURE AND URINE FORMATION
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Detection of breast cancer in young women
Authors: G. J. Lesnick
Journal: JAMA (1977)

The method of discovery of breast tumors in young women was determined for 106 patients less than 45 years of age treated for breast cancer from 1967 through 1975. The patients detected 84% of the tumors themselves. Physical examinations by physicians detected 14% of the tumors. Two percent were noted on mammography in the absence of clinical findings. Fifty-two patients had roentgenographic examination of their breasts prior to biopsy. Sixty-three percent of these examinations failed to demonstrate the cancer. The report of a normal roentgenogram contributed to a decision to defer surgical treatment in 15 instances. These 15 patients had more advanced tumors at operation. (<i>JAMA</i>237:967-969, 1977)
April Through June 1991 Table Reporting Alcohol Involvement in Fatal Motor-Vehicle Crashes
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparaison de lʼendoscopie assistée par capuchon et de l'endoscopie par vision latérale pour l'examen de la papille duodénale majeure: une étude croisée randomisée, contrôlée et de non-infériorité
Journal: Endoscopy (2019)

Le gold standard pour l’analyse de la papille dodénale majeure repose sur l’utilisation d’un duodénoscope. Toutefois, cet appareil n’est pas dsponible dans tout les centres, nécessite une formation sépciiqte et doit être combiné avec un appareil axial afin d’explorer l’enseble du tractuds digestif haut. Des études ont montré qu’il était possible d’explorer la papille en utilsatn un endoscope axial équipé d’un cap transparent. Dans ce numéro, deux études prospectives, randomisées, de non infériorité sont rapportées.
Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia,
Authors: Meagan A Jacoby, Michael Martin, Teresa Reineck, Peter Westervelt, John F. DiPersio, Amanda Cashen, Keith Stockerl-Goldstein, Geoffrey L. Uy, Ravi Vij, Camille N. Abboud
Journal: Blood (2011)
JAMA Internal Medicine
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Lauren Fischer, John Mcfadden, Donald Smith, Karen Boyd, Rochelle Lodder, Diane Cannon, Connie Manno, Fred Marshall, Laura Copyreaders, Catherine Adamcyzk, Jan Alden, Mary Clavey, Gillian Coerver-Connolly, Laura Dickens, Juliann King, Donna Tarsney, Caroline Thordsen, Wanda Assistant, Larry Bryant, Monica Mungle, Elaine Managers, Staff Gardner- Gullens, Fanny Brown, Paul Frank, Rachell Lozano, Michaela Mark, Kathryn Muskovich, J Neff, Kate Pezalla, Gale Saulsberry, Michael Berkwits, Michelle Kurzynski, Eric Butkus, Christopher Hastings, Craig Mccaffrey, Reuben Rios, Ronna Henry, Staff Bird, Alison Burke, Cassio Lynm, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Deanna Bellandi, Jim Periodical, Thomas Staff, Monica Smith, Jeffery Bonistalli Manager, Kathy Staff, Mirna Monal, Patricia Quilty, Thalia Moss, Tem Harrier, Susan Henning, Mark Thornbury, Tricia Castellano, Saskia Bolore, Gretchen Linder, Brian Mccartney, Rebecca Haas, Christine Hearne, Irma Lara, Audra Lawlor, Matt Herron, Elizabeth Solaro, Geoffrey Flick, Paul Gee Managers, Rick Bell, Michael Mcgraw, Sara Nagy, Stacy Staff, Millette Jackson-Bates, Karen Adams-Taylor, Karl Elvin, Sue Sherrill, Brian Shields Managers, David Antos, Chris Borden, Debbie Camp, Lydia Cruz, Diane Darnell, Colleen Kelly, Chris Meyer, Jaye Mize, Annemarie Neff, Sean O'donnell, Sean Ohlson, Phil O'leary, Ryan Patella, Susan Price, Denise Steinhauser, Production Services, Kim Boler, Rhonda Brown, Timothy Burke, Daniel Degroot, Jordynn Farrar, Euwanaha Joiner-Smith, Cindy Rendlen, Ellen Yoshihara, Circulation Services, Julie Burton, Dexter Golden, Erin Hinchcliff, Noemi Rivera, Geneine Van, Someren Composition, New Media, Gail Barrett, Regina Brownlee, Brenda Chandler-Grayer, Scott Curl, Amy Evers, Teri Hutchison, Mary Kuranda, Joshua Lampinen, Patricia Panek, La Son, Diggs Sledge, George Thomson Graphics, Joe Amft, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Daniel James, Judith Literskis, Teresa Omiotek, James Madara, Bernard Hengesbaugh, Jeffrey Tabas, San Francisco, Paul Varosy, Gregory Marcus, Nora Goldschlager, California Cme, Rebecca Larson, California Less, Is More, Deborah Grady, Mitchell Katz, Los Angeles, Patrick California, David Glidden, John Neuhaus, Kenneth Covinsky, Joseph Ross, New Haven, Raman Khanna, Kathleen Mckibbin, Katherine Gilhooley, Mary Kohut, Howard Bauchner, Rita Redberg, Rosemary Gibson, Shannon Brownlee, Robert Steinbrook, Judyann Bigby, Ezekiel Emanuel, Mark Feinglos, Chi-Yuan Hsu, Kurt Kroenke, Grace Lin, Mary Mcdermott, C Noel, Bairey Merz, Samia California, Robert Phillips, Michael Pignone, Chapel Hill, North Carolina, Judith Prochaska, Bruce Psaty, Kathryn Rexrode, Mary Tinetti, Nicolas Rodondi, Iona Heath
Journal: JAMA Internal Medicine (2014)
Correction
Journal: BMJ (1960)

ANY QUESTIONS? of the gene.The risk of epilepsy in a child of a patient with epilepsy is about 3 to 4%,1 2 but here, since the patient has a sister similarly affected, the risk is probably rather higher, but not a serious risk.The risk of deaf-mutism appearing in the children is difficult to assess.Most genetically determined forms of deaf-mutism appear to be due to one of a group of autosomal recessive genes.3'These could be responsible here only if the deaf-mute sister who has a deaf-mute child has married a carrier of the same gene, and other genetic mechanisms might be concerned in this family.Nevertheless, the risk of deaf- mutism in the patient's children is probably not high.The main risk, therefore, is the l-in-4 risk of haemophilia in the patient's sons.
Evaluation of a general anesthetic. Isoflurane
Authors: H. W. Linde
Journal: JAMA (1981)

Isoflurane is a nonflammable halogenated ether used as an inhalational anesthetic. It has physical, pharmacologic, and clinical properties similar to those of halothane and enflurane; however, it differs in important respects from both. It is a more potent muscle relaxant than halothane and does not have the CNS irritant properties of enflurane. It does not sensitize the myocardium to epinephrine as does halothane, and it undergoes less biotransformation than either enflurane or halothane. (<i>JAMA</i>1981;245:2335-2336)
Abstract 3740: Ionizing radiation-induced transcriptomic changes in triple-negative breast cancer cells reveal putative mechanisms of treatment resistance
Authors: Victor T. Lin, Tshering D. Lama-Sherpa, Rajeev S. Samant, Lalita A. Shevde
Journal: Cancer Research (2019)

Abstract Breast cancer is the most common malignancy and the second leading cause of cancer-associated deaths in women. Of these, triple-negative breast cancers (TNBCs) remain the most difficult to treat. Unlike hormone-driven breast cancers, TNBCs that remain in remission past the five-year mark rarely relapse and are considered functionally cured. Thus, investigating mechanisms of treatment resistance in order to improve remission rates is of paramount importance. In this study, we use RNA-Seq to analyze global transcriptomic changes in TNBC cells in response to DNA damage induced by ionizing radiation (IR). Applying gene set enrichment analysis (GSEA), we have identified a number of expression signatures that represent putative mechanisms of resistance to treatment. In prior work, we have demonstrated the role of the transcription factor Gli1, the terminal effector of the Hedgehog (Hh) signaling pathway, in regulating the expression of DNA repair proteins in response to genotoxic damage with cisplatin. We have previously shown that Hh inhibition blunts the expected upregulation of specific proteins involved in single-strand DNA repair in ovarian cancer cells. Here, we expand on our earlier studies by examining TNBC cells with high levels of Hh activity and querying how global transcriptomic changes in response to IR are altered by Hh inhibition. Our data suggest that rational manipulation of these pathways may sensitize TNBCs to treatment and improve the functional cure rate of these tumors. Citation Format: Victor T. Lin, Tshering D. Lama-Sherpa, Rajeev S. Samant, Lalita A. Shevde. Ionizing radiation-induced transcriptomic changes in triple-negative breast cancer cells reveal putative mechanisms of treatment resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3740.
Retina
Authors: Richard Feist
Journal: JAMA (1989)

The neurosensory retina is the only portion of the central nervous system exposed to the light of the outside world. Despite previous advances, many mysteries remain regarding the function and dysfunction of this vital tissue. This is underscored by the morbidity retinal diseases carry in the United States, with diabetic retinopathy and age-related macular degeneration ranking as the two leading causes of irreversible legal blindness in the United States.<sup>1</sup> In comparison with the medical sciences as a whole, the history of vitreoretinal ophthalmology is short and kinetic, with many of the field's innovators still alive and practicing. In the United States the beginnings of the subspecialty were with Charles Schepens, who popularized external scleral buckling techniques as the first modern treatment for retinal detachment in the 1940s and 1950s. Further advances followed in the 1950s and 1960s with the origination of fluorescein angiography by Novotny and Alvis, Meyer-Schwickerath's description
Predictive value of thymidylate synthase (ts) gene polymorphism for response to 5-FU in advanced colorectal cancer (CRC): Role of chromosome 18p allelic loss
Authors: A.-C. Dupont Gossart, J. Viguier, V. Boige, C. Miquel, M. Pocard, M. Ducreux, J.-C. Sabourin, F. Praz
Journal: Journal of Clinical Oncology (2004)

3603 Background: The variable number of tandem repeat of the TS promoter gene (mainly 2 or 3 28bp repeats) has been shown to influence response to 5-FU therapy. Because TS is located on chromosome 18p11.32, a region frequently lost in CRC, the impact of TS allelic imbalance needs to be taken into account to assess the predictive value of TS genotype for tumor response to 5-FU in advanced CRC. Methods: TS polymorphism was determined in both normal and tumor tissues obtained from 56 patients with advanced CRC (37 males, median age 54.5 yrs) treated with 5-FU as first line chemotherapy. In order to discriminate 2R/loss and 3R/loss TS genotypes from 2R/2R and 3R/3R, respectively, 18p allelic loss was analyzed in tumor tissues, using polymorphic markers located in the region of TS. Results: : In normal tissue, the distribution of TS genotype was: 2R/2R, 16% (n=9); 2R/3R, 47% (n=27); 3R/3R, 35% (n=20). Objective response rate (ORR) to 5-FU was 39%. The ORR was not different between the 3R/3R (50%), 2R/3R (37%), and 2R/2R (22%) genotypes. When TS polymorphism was studied in primary tumors (n=32), a better ORR was observed in patients with 3R/3R genotype (56%) compared to patients with 2R/3R and 2R/2R genotypes (22% and 0%, respectively; p=0.06). When loss of TS was considered, ORR was significantly better in patients with 3R/3R genotype (60%) compared to patients with either 3R/loss –2R/3R (35%) or 2R/2R –2R/loss (0%) genotypes (p=0.03). Conversely, ORR was not correlated to the TS genotype in metastasis (n=24), whatever loss of TS was considered or not. Conclusions: TS polymorphism in primary tumor may predict response to 5-FU in advanced CRC when loss of TS is considered. Specifically, the corrected 3R/3R TS genotype is associated with a better response to 5-FU first line chemotherapy. No significant financial relationships to disclose.
Hepatitis B virus transgenic mice: Insights into the virus and the disease
Authors: Francis V. Chisari
Journal: Hepatology (1995)

The hepatitis B virus (HBV) is a noncytopathic, enveloped virus with a circular double-stranded DNA genome that causes acute and chronic necroinflammatory liver disease and hepatocellular carcinoma.'HBV infection acquired in adult life is often clinically inapparent, and most acutely infected adults recover completely from the disease and clear the virus.Rarely, however, the acute liver disease may be so severe that the patient dies of fulminant hepatitis.A small fraction, perhaps up to 5%, of acutely infected adults become persistently infected by the virus and develop chronic liver disease of varying severity.Neonatally transmitted HBV infection, however, is rarely cleared, and more than 90% of such children become chronically infected.Because HBV is commonly spread from infected mother to newborn infant in highly populated areas of Africa and Asia, several hundred million people throughout the world are persistently infected by HBV for most of their lives and suffer varying degrees of chronic liver disease, which greatly increases their risk of developing cirrhosis and hepatocellular carcinoma (HCC).Indeed, the risk of HCC is increased 100fold in patients with chronic hepatitis, and the lifetime risk of HCC in males infected at birth approaches 40%.2Accordingly, a large fraction of the world's population suffers from and dies of these late complications of HBV infection.It is generally thought that HBV is not directly cytopathic for the hepatocyte but that the associated liver diseases are caused by the immune response to viral antigens expressed by infected hepatocytes.HBV-in-